Fundraising Fox
Rubius Therapeutics
Cambridge, US · Founded 2013 · Delaware corporation · 18 employees on LinkedIn · 4 known investors
Find your way into Rubius Therapeutics
Sign up to find every way you can get introduced to Rubius Therapeutics
- Your email: who you already know at Rubius Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Rubius Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
DE
David EpsteinNamed on SEC filing
HF
Harvey F. LodishNamed on SEC filing
MR
Michael RosenblattNamed on SEC filing
RP
RS
Board
NB
PB
Peter Barton HuttBoard director
Investors · 4
Flagship PioneeringreportedCambridge · $500K – $10Mvia Noubar Afeyan · board
How we know: board seat on SEC Form D · funding news · fiercebiotech.com · Not right? Tell us
Flagship VenturesreportedCambridge
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
Flagship VentureLabs
Reported raises · per SEC filings
Form D private placements$216.2M disclosed across 2 rounds · 2017–2018
▶$101.2MraisedMar 2018 · 27 investors · BiotechnologyRule 506(b)
▶$101.2MraisedMar 2018 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher L. CarpenterExecutive Officer
- Torben Straight NissenExecutive Officer, Director
- Robert S. LangerDirector
- Noubar B. AfeyanDirector
- Francis CussDirector
- Catherine SohnDirector
- Michael RosenblattDirector
- Roger PomerantzDirector
- Joanne ProtanoExecutive Officer
- David EpsteinDirector
- Andrew OhExecutive Officer
- Offering amount
- $101.2M
- Amount sold
- $101.2M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$115MraisedJun 2017 · 16 investors · BiotechnologyRule 506(b)
▶$115MraisedJun 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter Barton HuttDirector
- David EpsteinDirector
- Harvey F. LodishDirector
- Michael RosenblattDirector
- Roger PomerantzDirector
- Robert S. LangerDirector
- Noubar B. AfeyanDirector
- Torben Straight NissenExecutive Officer, Director
- Joanne ProtanoExecutive Officer
- Offering amount
- $120M
- Amount sold
- $115M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Rubius Therapeutics mafia →6 people who came through Rubius Therapeutics went on to found or lead other companies.
Noubar AfeyanDirectorFounded ProFound Therapeutics +15Avak KahvejianFounding President & CEOFounded ProFound Therapeutics +5Robert LangerDirectorFounded Lyndra +2ROGER POMERANTZDirectorFounded Seres TherapeuticsKris ElverumSVP of Business Development and StrategyFounded ロゴマーク：AIRNAPablo J. CagnoniPresident and Chief Executive OfficerFounded Tizona Therapeutics, Inc.
Frequently asked questions
- Who are Rubius Therapeutics's investors?
- Rubius Therapeutics's investors include Flagship Pioneering, Flagship Ventures, Kendall Capital Partners.
- How much funding has Rubius Therapeutics raised?
- Rubius Therapeutics has disclosed $216.2M raised across 2 rounds.
- Where is Rubius Therapeutics headquartered?
- Rubius Therapeutics is headquartered in Cambridge, US.